D-0730-2016 Class II Terminated

Recalled by Genzyme Corporation — Cambridge, MA

FDA drug recall D-0730-2016 was initiated by Genzyme Corporation on Feb 16, 2016 and is designated Class II. Reason for recall: Presence of Particulate Matter: Glass particles found in the product after reconstitution. The recall status is terminated (terminated Mar 2, 2017). Affected quantity: 4669 Cartons.

Recall details

Product Type
Drugs
Report Date
Mar 9, 2016
Initiation Date
Feb 16, 2016
Termination Date
Mar 2, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4669 Cartons

Product description

Thyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For intramuscular injection only, Rx Only, Two vials per Carton, Carton contains 2 vials of Thyrogen, Dilute with Sterile Water for Injection, Storage: store at 2-8 C, Manufactured by: Genzyme Corporation, Northborough, MA 01532 USA, Marketing Authorization holder: Sanofi-Aventis, NDC 58468-0030-2.

Reason for recall

Presence of Particulate Matter: Glass particles found in the product after reconstitution.

Distribution pattern

Nationwide, Puerto Rico and Malaysia, Taiwan, Brazil, and Israel.

Code information

Lot #s: E4029Y03, E4029Y04, E4029Y06, E4029Y07, Exp 12/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0730-2016
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Genzyme Corporation? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0730-2016. Report a data issue: hello@regdatalab.com.